A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib.

Trial Profile

A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Carotuximab (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 13 May 2015 As per a TRACON pharmaceuticals media release, National Cancer Institute (NCI) reported positive results from this study at the 2015 ASCO Gastrointestinal Cancers Symposium.
    • 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top